Patents Assigned to Tularik
  • Publication number: 20040248882
    Abstract: Modulators of PPAR&ggr; activity are provided which are useful in pharmaceutical compositions and methods for the treatment of conditions such as type II diabetes and obesity.
    Type: Application
    Filed: March 25, 2004
    Publication date: December 9, 2004
    Applicant: Tularik Inc.
    Inventors: Lawrence R. McGee, Jonathan B. Houze, Steven M. Rubenstein
  • Publication number: 20040235911
    Abstract: Hydroxyamidines and related compounds are provided which are suitable as antibacterial agents.
    Type: Application
    Filed: June 25, 2004
    Publication date: November 25, 2004
    Applicant: Tularik Inc.
    Inventors: Leping Li, Xiaoqi Chen, Pingchen Fan, Jeffrey Thomas Mihalic, Serena Cutler
  • Patent number: 6821750
    Abstract: The present invention provides nucleic acids encoding a novel ABC family cholesterol transporter, ABCG8. The herein-disclosed sequences can be used for any of a number of purposes, including for the diagnosis and treatment of cholesterol-associated disorders, including sitosterolemia, and for the identification of molecules that associate with and/or modulate the activity of ABCG8.
    Type: Grant
    Filed: November 20, 2001
    Date of Patent: November 23, 2004
    Assignees: Tularik Inc., Board of Regents, The University of Texas System
    Inventors: Helen H. Hobbs, Bei Shan, Robert Barnes, Hui Tian
  • Patent number: 6822001
    Abstract: Combination therapies are provided for the treatment of proliferative disorders which use a pentafluorobenzenesulfonamide of formula I and an antineoplastic agent such as gemcitabine or paclitaxel.
    Type: Grant
    Filed: November 2, 2001
    Date of Patent: November 23, 2004
    Assignee: Tularik Inc.
    Inventors: Susan Schwendner, Pieter Timmermans, Jacqueline Walling
  • Patent number: 6818419
    Abstract: The present invention provides nucleic acids and polypeptides for IRAK-4, a novel member of the IRAK family of protein kinases. Members of the IRAK family are indispensable signal transducer for members of the IL-1R/Toll family of transmembrane receptors, including IL-1 receptors, IL-18 receptors and LPS receptors. IRAK-4 sequences from human and mouse are provided, as are methods for identifying compounds useful in the treatment or prevention of inflammatory diseases.
    Type: Grant
    Filed: January 11, 2001
    Date of Patent: November 16, 2004
    Assignee: Tularik Inc.
    Inventors: Holger Wesche, Shyun Li
  • Patent number: 6809104
    Abstract: Compounds having the formula: wherein L is a bond or (C1-C4)alkylene, R″ is hydrogen or (C1-C8)alkyl, and R1, R2, R4, R, R′, and the subscript n are as described herein, are provided, which are useful in the treatment and/or prevention of a condition or disorder mediated by a G-protein coupled receptor. Pharmaceutical compositions and methods of using these compounds for the treatment and/or prevention of a condition or disorder mediated by a G-protein coupled receptor, such as eating disorders, obesity, anxiety disorders and mood disorders, are also provided.
    Type: Grant
    Filed: November 6, 2002
    Date of Patent: October 26, 2004
    Assignee: Tularik Inc.
    Inventors: Xiaoqi Chen, Pingchen Fan, Juan Jaen, Leping Li, Mike Lizarzaburu, Jeffrey Thomas Mihalic, Stephen Joseph Shuttleworth
  • Publication number: 20040209871
    Abstract: Compounds, pharmaceutical compositions and methods that are useful in the treatment or prevention of metabolic and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the activity of proteins involved in lipid metabolism and cell proliferation.
    Type: Application
    Filed: November 21, 2003
    Publication date: October 21, 2004
    Applicants: Tularik Inc., Japan Tobacco Inc.
    Inventors: Brian M. Fox, Noboru Furukawa, Xiaolin Hao, Kiyosei Iio, Takashi Inaba, Simon M. Jackson, Frank Kayser, Marc Labelle, Kexue Li, Takuya Matsui, Dustin L. McMinn, Nobuya Ogawa, Steven M. Rubenstein, Shoichi Sagawa, Kazuyuki Sugimoto, Masahiro Suzuki, Masahiro Tanaka, Guosen Ye, Atsuhito Yoshida, Jian Zhang
  • Patent number: 6794379
    Abstract: Compounds, compositions and methods that are useful in the treatment of inflammatory and immune conditions and diseases are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of a chemokine receptor. The subject methods are useful for the treatment of inflammatory and immunoregulatory disorders and diseases, such as multiple sclerosis, rheumatoid arthritis and type I diabetes.
    Type: Grant
    Filed: June 6, 2002
    Date of Patent: September 21, 2004
    Assignee: Tularik Inc.
    Inventors: Julio C. Medina, Michael G. Johnson, An-Rong Li
  • Publication number: 20040176426
    Abstract: The present invention provides compounds, pharmaceutical compositions and methods that are useful in modulating the farnesoid X receptor (FXR). As FXR is involved in negatively controlling the expression level of cholesterol 7&agr;-hydroxylase (cyp7a), the rate-limiting enzyme involved in the oxidative metabolism of cholesterol into bile acids, the compounds described herein find utility in treating diseases associated with abnormally high or low cholesterol levels. In certain aspects, the FXR modulators (e.g., antagonists) described herein block the negative feed-back downregulation of cyp7a expression produced by certain cholic acids, the endogenous ligands for FXR. Moreover, as FXR forms heterodimers with the retinoid X receptor (RXR) in some cell types, modulation of the level of FXR activity in cells has a wide range of effects on a variety of biological processes which are mediated by RXR or other RXR-interacting proteins such as PPAR&ggr; and PPAR&agr;.
    Type: Application
    Filed: March 4, 2004
    Publication date: September 9, 2004
    Applicant: Tularik, Inc.
    Inventors: Jonathan Houze, Sharon McKendry, Joshua P. Gergely, Yi Xia, Bei Shan, Frank Kayser
  • Publication number: 20040176409
    Abstract: Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by PPAR&ggr;. In particular, the compounds of the invention modulate the function of PPAR&ggr;. The subject methods are particularly useful in the treatment and/or prevention of diabetes, obesity, hypercholesterolemia, rheumatoid arthritis and atherosclerosis.
    Type: Application
    Filed: November 20, 2003
    Publication date: September 9, 2004
    Applicants: Tularik Inc, Japan Tobacco, Inc.
    Inventors: Lawrence R. McGee, Jonathan B. Houze, Steven M. Rubenstein, Atsushi Hagiwara, Noboru Furukawa, Hisashi Shinkai
  • Patent number: 6780858
    Abstract: Hydroxyamidines and related compounds are provided which are suitable as antibacterial agents.
    Type: Grant
    Filed: January 12, 2001
    Date of Patent: August 24, 2004
    Assignee: Tularik Inc.
    Inventors: Leping Li, Xiaoqi Chen, Pingchen Fan, Jeffrey Thomas Mihalic, Serena Cutler
  • Patent number: 6777446
    Abstract: The present invention provides compounds, pharmaceutical compositions and methods that are useful in modulating the farnesoid X receptor (FXR). As FXR is involved in negatively controlling the expression level of cholesterol 7&agr;-hydroxylase (cyp7a), the rate-limiting enzyme involved in the oxidative metabolism of cholesterol into bile acids, the compounds described herein find utility in treating diseases associated with abnormally high or low cholesterol levels. In certain aspects, the FXR modulators (e.g., antagonists) described herein block the negative feed-back downregulation of cyp7a expression produced by certain cholic acids, the endogenous ligands for FXR. Moreover, as FXR forms heterodimers with the retinoid X receptor (RXR) in some cell types, modulation of the level of FXR activity in cells has a wide range of effects on a variety of biological processes which are mediated by RXR or other RXR-interacting proteins such as PPAR&ggr; and PPAR&agr;.
    Type: Grant
    Filed: August 31, 2001
    Date of Patent: August 17, 2004
    Assignee: Tularik, Inc.
    Inventors: Jonathan Houze, Sharon McKendry, Joshua P. Gergely, Yi Xia, Bei Shan, Frank Kayser
  • Publication number: 20040152132
    Abstract: The invention provides solid support synthetic methods for producing combinatorial libraries of modulators of LXRs. The combinatorial libraries thus produced are useful both as diagnostic indicators of LXR&agr; function and as pharmacologically active agents. The combinatorial libraries find particular use in the treatment of disease states associated with cholesterol metabolism, particularly atherosclerosis and hypercholesterolemia.
    Type: Application
    Filed: December 30, 2003
    Publication date: August 5, 2004
    Applicants: Tularik Inc., Sumitomo Pharmaceuticals Co., Ltd.
    Inventors: Julio Medina, Naonori Imazaki
  • Patent number: 6770648
    Abstract: Modulators of PPAR&ggr; activity are provided which are useful in pharmaceutical compositions and methods for the treatment of conditions such as type II diabetes and obesity.
    Type: Grant
    Filed: July 30, 2002
    Date of Patent: August 3, 2004
    Assignee: Tularik Inc.
    Inventors: Lawrence R. McGee, Jonathan B. Houze, Steven M. Rubenstein
  • Patent number: 6740682
    Abstract: The novel compound 3-amidinobenzoyl-D-phenylglycine-3-phenylanilide is useful as a serine protease inhibitor.
    Type: Grant
    Filed: November 19, 2001
    Date of Patent: May 25, 2004
    Assignee: Tularik Limited
    Inventor: John Walter Liebeschuetz
  • Publication number: 20040097485
    Abstract: Compounds, compositions and methods that are useful in the treatment of inflammatory, immunoregulatory, metabolic, infectious and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, metabolism, infection and cell proliferation. The subject compounds contain a fused heterobicyclic ring.
    Type: Application
    Filed: September 19, 2003
    Publication date: May 20, 2004
    Applicant: Tularik Inc.
    Inventors: Simon A. Burkitt, Mario G. Cardozo, Timothy D. Cushing, Michael R. DeGraffenreid, Christopher N. Farthing, Xiaolin Hao, Juan C. Jaen, Xian Yun Jiao, David J. Kopecky, Marc Labelle, Sarah E. Lively, Dustin L. McMinn, Sven P. Rasmussen, Youngsook Shin, Andrew Smith, Marie-Louise Smith
  • Patent number: 6727267
    Abstract: Compounds, compositions and methods are provided that are useful in the treatment and prevention of certain viral infections and associated diseases. In particular, the compounds of the invention inhibit the activity of a viral RNA polymerase. The subject methods are particularly useful in the treatment of diseases causes by hepatitis C virus infection.
    Type: Grant
    Filed: April 5, 2001
    Date of Patent: April 27, 2004
    Assignee: Tularik Inc.
    Inventors: Juan C. Jaen, Jay P. Powers
  • Publication number: 20040039035
    Abstract: Compounds and compositions are provided that bind to the CCR4 chemokine receptor and which are useful for treating diseases associated with CCR4 activity, such as contact hypersensitivity.
    Type: Application
    Filed: September 2, 2003
    Publication date: February 26, 2004
    Applicants: Tularik Inc., ChemoCentryx, Inc.
    Inventors: Tassie Collins, Daniel J. Dairaghi, Hossen Mahmud, Brian E. McMaster, Julio C. Medina, Thomas J. Schall, Feng Xu, Xuemei Wang
  • Publication number: 20040029232
    Abstract: The invention provides isolated nucleic acid and amino acid sequences of four novel G-protein coupled receptors that are amplified in breast cancer cells, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of G-protein coupled receptors.
    Type: Application
    Filed: August 4, 2003
    Publication date: February 12, 2004
    Applicant: Tularik Inc.
    Inventors: Scott Powers, Jianxin Yang, Gene Cutler
  • Patent number: 6682898
    Abstract: This invention provides receptor peptides that have a high affinity for STAT4 and STAT6 polypeptides. Also provided are assays that are useful for identifying compounds that modulate the interaction between STAT4 and STAT6 polypeptides and their respective cellular promoters. The assays are amenable to high throughput screening.
    Type: Grant
    Filed: March 26, 2001
    Date of Patent: January 27, 2004
    Assignee: Tularik Inc.
    Inventors: Pengguang Wu, Judi McKinney